AC Immune (ACIU)
(Delayed Data from NSDQ)
$3.54 USD
-0.03 (-0.84%)
Updated May 24, 2024 04:00 PM ET
After-Market: $3.53 -0.01 (-0.28%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
AC Immune [ACIU]
Reports for Purchase
Showing records 21 - 40 ( 62 total )
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Tracers, Vaccines, and Non-AD Programs Might Have a Long-Term Growth Potential for AC Immune
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Considerations for Crenezumab?s Phase 2 Top-Line Data Readout in 1H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
AC Immune?s R&D Day Showcased the Strength of Non-AD Programs with Potential for Future Growth
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
AC Immune?s Alpha-Synuclein Tracer--A Potential Breakthrough for Alpha Synucleopathies
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Bird''s Eye View of Disease-Modifying Targets of Parkinson''s Disease-AD/PD 2022 Live from Barcelona
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Do You Know About the Current State-of-the-Art AD/PD Biomarkers?
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
ACI-35.030 Gets It Right, Selectively Hits Pathological Tau in the Phase 1b/2a Interim Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Modest Effect of Semorinemab Not Enough for Mild-to-Moderate AD Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Expectations from the Biomarker Data at CTAD 2021; Reit Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Company: AC Immune
Industry: Medical - Biomedical and Genetics
First Cognitive Results for Anti-Tau Monoclonal Antibody Semorinemab Pushes Tau to the Fore
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Progress Across Diversified Neurodegeneration-Focused Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Addition of A Late-Stage PD01 Program Strengthens PD Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Expansion of Phase 1b/2a phospho-Tau Vaccine Might Catalyze the ACI-035.030 Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
2021 Is All about Anti-Tau and Anti-Abeta Vaccines?Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Morphomer Platform AC Immune''s Chamber of Secrets Keep Pipeline Energized
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
Diversified Portfolio and Multi-Prong Approach can Drive Growth in 2021; Reit Buy and Raising PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: AC Immune
Industry: Medical - Biomedical and Genetics
ACI-24-Key Takeaways from the Global Down Syndrome Symposium
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A